Study identifier:D3250C00024
ClinicalTrials.gov identifier:NCT05692180
EudraCT identifier:N/A
CTIS identifier:2022-501344-14-00
Efficacy and Safety of Benralizumab in Paediatric Patients with Severe Eosinophilic Asthma (DOMINICA)
asthma
Phase 3
No
Benralizumab, Placebo
All
200
Interventional
6 Years - 18 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
PAREXEL
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Benralizumab Patients will receive Benralizumab as an active solution via a subcutaneous (SC) injection. | Drug: Benralizumab Benralizumab active solution will be administered SC to the patients. |
Placebo Comparator: Placebo Patients will receive a matching solution of the placebo via SC injection. | Drug: Placebo Placebo solution will be administered SC to the patients. |